Vagus nerve stimulation (VNS) shows a positive treatment effect and improved quality of life (QoL) among patients with ...

NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.

In adults 65 or older, excluding regional heterogeneity, those with multimorbidity vs those without were more likely to develop geriatric depression.

Stimulating either of a pair of crucial nerves that carry messages from the brain to several major organs could be an ...

Neumora Therapeutics Inc. (NASDAQ: NMRA) nosedived by more than 80 percent during pre-market trading following disappointing ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an effic ...

Navacaprant is the company's main product candidate, and was measured using the Montgomery-Åsberg Depression Rating Scale, or MADRS, a 10-question diagnostic questionnaire used by mental-health ...

Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...

Neumora Therapeutics (NASDAQ:NMRA) announced Thursday that its Phase 3 KOASTAL-1 study for its lead asset navacaprant ...

Neumora Therapeutics (NMRA) crashed after its Phase 3 study for its lead asset navacaprant in major depressive disorder ...

The yearlong trial of 493 adults with an average age of 53 ... which was for the Montgomery-Asberg Depression Rating Scale, or MADRAS, to show more improvement in the active VNS group than in ...